LPAR3

edit
Receptor lizofosfatidne kiseline 3
Identifikatori
SimboliLPAR3; EDG7; Edg-7; HOFNH30; LP-A3; LPA3; RP4-678I3
Vanjski IDOMIM: 605106 MGI: 1929469 HomoloGene: 8123 IUPHAR: LPA3 GeneCards: LPAR3 Gene
Ontologija gena
Molekularna funkcija • vezivanje G-protein alfa podjedinice
• aktivnost G-protein spregnutog receptora
• proteinsko vezivanje
• fosfolipidno vezivanje
Celularna komponenta • citoplazma
• ćelijska membrana
• integralno sa ćelijskom membranom
• ćelijska površina
Biološki proces • activacija MAPK aktivnosti
• signalni put G-protein spregnutog receptora
• aktivacija fosfolipaze C
• povišenje koncentracije citozolnih jona kalcijuma
Pregled RNK izražavanja
podaci
Ortolozi
VrstaČovekMiš
Entrez2356665086
EnsemblENSG00000171517ENSMUSG00000036832
UniProtQ9UBY5Q9EQ31
RefSeq (mRNA)NM_012152.2NM_022983.4
RefSeq (protein)NP_036284.1NP_075359.1
Lokacija (UCSC)Chr 1:
85.28 - 85.36 Mb		Chr 3:
145.88 - 145.95 Mb
PubMed pretraga[1][2]

Receptor lizofosfatidne kiseline 3 (LPA3) je protein koji je kod ljudi kodiran LPAR3 genom.[1][2] LPA3 je G protein spregnuti receptor za koji se vezuje lipidni signalni molekul lizofosfatidna kiselina (LPA).[3]

Funkcija

Ovaj protein je član familije I G protein spregnutih receptora, kao i EDG familije. On funkcioniše kao ćelijski receptor za lizofosfatidnu kiselinu i podstiče mobilizaciju kalcijuma. Ovaj receptor se predominantno spreže sa G(q/11) alfa proteinima.[1]

Reference

  1. ↑ 1,0 1,1 „Entrez Gene: LPAR3 Lysophosphatidic acid receptor 3”. 
  2. ↑ Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K (September 1999). „Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid”. J. Biol. Chem. 274 (39): 27776–85. DOI:10.1074/jbc.274.39.27776. PMID 10488122. 
  3. ↑ Choi JW, Herr DR, Noguchi K, Yung YC, Lee C-W, Mutoh T, Lin M-E, Teo ST, Park KE, Mosley AN, Chun J (January 2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology 50 (1): 157–186. DOI:10.1146/annurev.pharmtox.010909.105753. PMID 20055701. [mrtav link]

Literatura

  • Contos JJ, Ishii I, Chun J (2001). „Lysophosphatidic acid receptors.”. Mol. Pharmacol. 58 (6): 1188–96. PMID 11093753. 
  • Im DS, Heise CE, Harding MA, et al. (2000). „Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate.”. Mol. Pharmacol. 57 (4): 753–9. PMID 10727522. 
  • Fitzgerald LR, Dytko GM, Sarau HM, et al. (2000). „Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid.”. Biochem. Biophys. Res. Commun. 273 (3): 805–10. DOI:10.1006/bbrc.2000.2943. PMID 10891327. 
  • Tokumura A, Sinomiya J, Kishimoto S, et al. (2002). „Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.”. Biochem. J. 365 (Pt 3): 617–28. DOI:10.1042/BJ20020348. PMC 1222725. PMID 11982483. 
  • Hama K, Bandoh K, Kakehi Y, et al. (2002). „Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.”. FEBS Lett. 523 (1-3): 187–92. DOI:10.1016/S0014-5793(02)02976-9. PMID 12123830. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. DOI:10.1073/pnas.242603899. PMC 139241. PMID 12477932. 
  • Cremers B, Flesch M, Kostenis E, et al. (2003). „Modulation of myocardial contractility by lysophosphatidic acid (LPA).”. J. Mol. Cell. Cardiol. 35 (1): 71–80. DOI:10.1016/S0022-2828(02)00279-1. PMID 12623301. 
  • Fujita T, Miyamoto S, Onoyama I, et al. (2003). „Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.”. Cancer Lett. 192 (2): 161–9. DOI:10.1016/S0304-3835(02)00713-9. PMID 12668280. 
  • Jin Y, Knudsen E, Wang L, Maghazachi AA (2003). „Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization.”. Eur. J. Immunol. 33 (8): 2083–9. DOI:10.1002/eji.200323711. PMID 12884281. 
  • Xing Y, Ganji SH, Noh JW, Kamanna VS (2005). „Cell density-dependent expression of EDG family receptors and mesangial cell proliferation: role in lysophosphatidic acid-mediated cell growth.”. Am. J. Physiol. Renal Physiol. 287 (6): F1250–7. DOI:10.1152/ajprenal.00342.2003. PMID 15292052. 
  • Gerhard DS, Wagner L, Feingold EA, et al. (2004). „The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”. Genome Res. 14 (10B): 2121–7. DOI:10.1101/gr.2596504. PMC 528928. PMID 15489334. 

Vidi još

  • Receptor lizofosfatidne kiseline

Spoljašnje veze

  • „Lysophospholipid Receptors: LPA3”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Arhivirano iz originala na datum 2016-03-03. 
  • p
  • r
  • u
Klasa A: Rodopsinu slični
α1 (A, B, D) • α2 (A, B, C) • β1 • β2 • β3
Adenozinski (A1, A2A, A2B, A3) • P2Y (1, 2, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14)
(svi osim 5-HT3) 5-HT1 (A, B, D, E, F) • 5-HT2 (A, B, C) • 5-HT (4, 5A, 6, 7)
Drugi
Acetilholin (M1, M2, M3, M4, M5) • Dopamin (D1, D2, D3, D4, D5) • Histamin (H1, H2, H3, H4) • Melatonin (1A, 1B, 1C) • TAAR (1, 2, 3, 5, 6, 8, 9)
Metaboliti i
signalni molekuli
CysLT (1, 2) • LTB4 (1, 2) • FPRL1 • OXE • Prostaglandin (DP (1, 2), EP (1, 2, 3, 4), FP) • Prostaciklin • Tromboksan
Drugi
Žučna kiselina • Kanabinoidni (CB1, CB2, GPR (18, 55, 119)) • EBI2 • Estrogen • Slobodna masna kiselina (1, 2, 3, 4) • Laktat  • Lizofosfatidna kiselina (1, 2, 3, 4, 5, 6)  • Lizofosfolipid (1, 2, 3, 4, 5, 6, 7, 8) • Niacin (1, 2) • Oksoglutarat • PAF • Sfingozin-1-fosfat (1, 2, 3, 4, 5) • Sukcinat
Peptid
B/W (1, 2) • FF (1, 2) • S • Y (1, 2, 4, 5) • Neuromedin (B, U (1, 2)) • Neurotenzin (1, 2)
Drugi
Anafilatoksin (C3a, C5a) • Angiotenzin (1, 2) • Apelin • Bombezin (BRS3, GRPR, NMBR) • Bradikinin (B1, B2) • Hemokin • Holecistokinin (A, B) • Endotelin (A, B) • Formil peptid (1, 2, 3) • FSH • Galanin (1, 2, 3) • GHB receptor • Gonadotropin-oslobađajući hormon (1, 2) • Grelin • Kispeptin • Luteinizirajući hormon/horiogonadotropin • MAS (1, 1L, D, E, F, G, X1, X2, X3, X4) • Melanokortin (1, 2, 3, 4, 5) • MCHR (1, 2) • Motilin • Opioidni (δ, κ, μ, Nociceptin & ζ, ali ne σ) • Oreksin (1, 2) • Oksitocin • Prokineticin (1, 2) • Prolaktin-oslobađajući peptid • Relaksin (1, 2, 3, 4) • Somatostatin (1, 2, 3, 4, 5) • Tahikinin (1, 2, 3) • Tirotropin • Tirotropin-oslobađajući hormon • Urotenzin-II • Vazopresin (1A, 1B, 2)
Razno
GPR (1, 3, 4, 6, 12, 15, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 31, 32, 33, 34, 35, 37, 39, 42, 44, 45, 50, 52, 55, 61, 62, 63, 65, 68, 75, 77, 78, 81, 82, 83, 84, 85, 87, 88, 92, 101, 103, 109A, 109B, 119, 120, 132, 135, 137B, 139, 141, 142, 146, 148, 149, 150, 151, 152, 153, 160, 161, 162, 171, 173, 174, 176, 177, 182, 183)
Drugi
Adrenomedulin • Mirisni • Opsin (3, 4, 5, 1LW, 1MW, 1SW, RGR, RRH) • Proteazom-aktivirani (1, 2, 3, 4) • SREB (1, 2, 3)
Klasa B: Sekretinu slični
GPR (56, 64, 97, 98, 110, 111, 112, 113, 114, 115, 116, 123, 124, 125, 126, 128, 133, 143, 144, 155, 157)
Drugi
Klasa C: Metabotropni
glutamat / feromon
TAS1R (1, 2, 3) • TAS2R (1, 3, 4, 5, 8, 9, 10, 12, 13, 14, 16, 19, 20, 30, 31, 38, 39, 40, 41, 42, 43, 45, 46, 50)
Drugi
Klasa F:
Frizzled / Zaglađeni
Uvojiti
Frizzled (1, 2, 3, 4, 5, 6, 7, 8, 9, 10)
Zaglađeni
B trdu: peptidi (nrpl/grfl/cytl/horl), receptori (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd, signalni putevi (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)